705 related articles for article (PubMed ID: 25444674)
1. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
Li H; Estabrook M; Jacoby GA; Nichols WW; Testa RT; Bush K
Antimicrob Agents Chemother; 2015 Mar; 59(3):1789-93. PubMed ID: 25534728
[TBL] [Abstract][Full Text] [Related]
6. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
[TBL] [Abstract][Full Text] [Related]
7.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
8. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN
Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
10. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.
Biedenbach DJ; Kazmierczak K; Bouchillon SK; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4239-48. PubMed ID: 25963984
[TBL] [Abstract][Full Text] [Related]
12. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
13. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
Bush K
Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.
Wang X; Zhang F; Zhao C; Wang Z; Nichols WW; Testa R; Li H; Chen H; He W; Wang Q; Wang H
Antimicrob Agents Chemother; 2014; 58(3):1774-8. PubMed ID: 24342639
[TBL] [Abstract][Full Text] [Related]
16. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
17. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
[TBL] [Abstract][Full Text] [Related]
18. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
19. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]